

# G - Index

## In this guide

### [In this guide](#)

1. [A - Index](#)
2. [B - Index](#)
3. [C - Index](#)
4. [D - Index](#)
5. [E - Index](#)
6. [F - Index](#)
7. [G - Index](#)
8. [H - Index](#)
9. [I - Index](#)
10. [J - Index](#)
11. [K - Index](#)
12. [L - Index](#)
13. [M - Index](#)
14. [N - Index](#)
15. [O - Index](#)
16. [P - Index](#)
17. [Q - Index](#)
18. [R - Index](#)
19. [S - Index](#)
20. [T - Index](#)
21. [U - Index](#)
22. [V - Index](#)
23. [W - Index](#)
24. [X - Index](#)
25. [Y - Index](#)
26. [Z - Index](#)

**Subject:**

**GADD45a GFP 'Green Screen' assay** **Year Page**

COM Discussion of 2010 42

**Subject:**

**Gallates (anti-oxidants in food)** **Year Page**

COM Discussion of 1992 37

**Subject:**

**Gellan gum** **Year Page**

COT Evaluation of 1993 13

**Subject:**

**Genetically modified** **Year Page**

Potatoes genetically modified to produce Galanthus nivalis  
1999 34

Lectin

**Subject:**

**Genetic susceptibility to cancer** **Year Page**

COC/COM Joint Symposium on 1998 33

Joint COC/COM symposium on genetic susceptibility to  
cancer 1998 35

COC scoping discussion on, 2000 110

**Subject:**

**Genomics and proteomics in toxicology, Year Page**  
**Joint meeting of COT/COC/COM on**

assessing their current and future potential as tools in regulatory  
risk assessments. 2001 24,  
109,  
143

use of genomics and proteomics in toxicology 2002 14

**Subject:**

**Genotoxic Consequences of Exposure to Year Page**  
**Mixtures of Food Derived Chemical**  
**Carcinogens**

COM review of FSA funded research on 2012 39

**Subject:**

**Genotoxic alkylating agents Year Page**

Thresholds for 2006 237

**Subject:****Year Page****Genotoxic carcinogens**

and DNA repair at low doses	2004	136, 176
Acute T25 – possible approach to potency ranking of single exposure	2006	279
The occurrence of “U” shaped dose dose-response curves	2003	196
European Food Safety Authority (EFSA) Advice to- chemicals that are genotoxic and carcinogenic	2005	141
Genotoxicity Testing of Impurities	2011	44
Interim Guidance on a Strategy for Genotoxicity Testing and Assessment of Impurities	2012	35

**Subject:****Year Page****Genotoxicity data**

Interpretation of, two-day 2019 workshop on 2020 48

**Subject:****Year Page****Genotoxicity, evidence for**

Genotoxicity testing and mutagenic hazard assessment of chemical substances. Consultation on a strategy for	2010	48
---	------	----

**Subject:****Genotoxicity of Nanomaterials**  
**Year Page**

A COM statement is currently being drafted 2011 45

in vitro genotoxicity testing of nanomaterials 2012 36

**Subject:****Genotoxicity of water and wastewater**  
**Year Page**

ISO Water quality standard: Determination of the genotoxicity of water and waste water using the umu test 1997 69

**Subject:****Genotype and environment interaction on susceptibility to cancer**  
**Year Page**

COC review of 2001 121

The investigation of interaction between genotype and chemicals in the environment on the induction of cancer 2002 132

Genotypes and chemicals in the environment on the induction of cancer in risk assessment. Interaction between 2010 59

**Subject:****Year Page****Germ cell mutagenesis**

investigating germ cell mutagenesis, the germ cell genome, meiosis and mutagenesis, the paternal age effect and aneuploidy in germ cells 2015 38

adverse outcome pathways 2016 34

consolidated summary of discussions 2017 43

Strategy for investigating germ cell mutagens 2003 138

Germ cell mutagens, COM guidance on testing 2021 53

**Subject:****Year Page****Ginger**

ongoing work on the COT contribution to the SACN risk assessment on nutrition and, ginger 2021 33

**Subject:****Year Page****Glucosamine and hepatotoxicity**

a very small number of individual case reports linking glucosamine and hepatitis 2008 20

case reports linking glucosamine and hepatitis 2009 15, 38

**Subject:**

<b>Gluten - timing of introduction into the infant diet</b>	<b>Year</b>	<b>Page</b>
and subsequent risk of developing coeliac disease or type 1 diabetes mellitus (T1DM)	2010	27
Further discussions on subsequent risk of developing coeliac disease or type 1 diabetes mellitus (T1DM)	2011	11

**Subject:**

<b>Guidance statement on the human health significance of chemical induced mutagenicity</b>	<b>Year</b>	<b>Page</b>
joint COC, COM and COT workshop on 'Whether epigenetics should be used in chemical risk assessment'	2017	55
information on chemically induced mutagenesis relevant to human health to the informed lay reader.	2013	45, 59

**Subject:**

<b>Guidance statements, COC</b>	<b>Year</b>	<b>Page</b>
Mode of Action, Human Relevance Framework and Margin of Exposure	2011	58
overarching statement G1, a statement on risk characterisation methods for carcinogens	2012	48

Overarching strategy (G01)	2019 53
Guidance statement update	2020 65
Guidance statement update on the use of biomarkers in carcinogenic risk assessment (G04)	2018 52
Hazard identification and characterisation: conduct and interpretation of animal carcinogenicity studies (G03), update of	2021 80
Guidance statement update	2018 52
Defining a point of departure and potency estimates in carcinogenic dose response (G05)	2018 52
Guidance statement update	2018 52
Further discussion papers on	2019 53
Risk characterisation methods (G06)	2018 52
Risk characterisation methods (G06) update of	2021 80
Alternatives to the 2-year bioassay (G07)	2018 52
Combined exposure to chemical carcinogens (G08)	2019 54
Less than lifetime exposure (G09)	2019 54

**Subject:**

**Year Page**

**Guidance statements, COM**



Guidance on use of (Q)SAR models to predict genotoxicity, evaluation of in vivo genotoxicity	2018 40
Guidance on Mutagenic Hazard Assessment and a Strategy for Genotoxicity Testing of Chemicals with Inadequate Genotoxicity Data	2011 43
Guidance on the use of (Q)SAR models to predict genotoxicity	2018 40
Guidance series, COM update of	2019 34
Guidance series, COM update of	2020 47
Guidance series, COM update of	2021 53
Guidance on assessment strategies and genotoxicity tests	2010 41
ICH guidelines: Genotoxicity: A standard battery for genotoxicity testing of pharmaceuticals (S2B) and consideration of the mouse lymphoma assay	1997 75
Germ cell mutagens, guidance on	2021 53
3D models, guidance on	2021 53
Testing strategies for nanomaterials, guidance on	2021 54
Testing strategies for impurities, update on guidance	2021 54
Use of QSAR models, guidance on	2021 54

**Subject:**

**Gut microbiome**

**Year Page**

statement on the effect of xenobiotics on the gut microbiome and the  
effect the gut microbiome on xenobiotics with reference to chemical risk assessment 2020 11